Literature DB >> 4432914

Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits.

H M Olson, D M Young, D J Prieur, A F LeRoy, R L Reagan.   

Abstract

Rabbits receiving adriamycin (ADR) on a chronic schedule developed significant histopathologic, ultrastructural and tissue electrolyte alterations of the ventricular myocardium. Rabbits that developed clinicopathologic evidence of cardiomyopathy with ADR had histologic lesions of the myocardium, including perivascular fibrosis, interstitial fibrosis and edema and myocytolysis. Ultrastructurally, large vacuoles resembling distended sarcoplasmic reticulum displaced the contractile elements and mitochondria, which were diminished in number within affected myocytes. Frequently, mitochondria appeared as electron-dense structures surrounded by layers of membranes resembling myelin figures. In addition, rabbits with cardiomyopathy had marked elevations in ventricular Ca, Na and H(2)O concentrations. Serum electrolytes were not significantly elevated, but lactic dehydrogenase (LDH) and creatine phosphokinase (CPK) were significantly increased, indicative of a cardiomyopathy. Rabbits receiving ADR but not developing clinicopathologic evidence of heart failure also had significant elevations in ventricular Ca, Na and H(2)O. Rabbits with no cardiomyopathy had no increases either in serum electrolyte concentrations or CPK and LDH levels. These studies indicate that marked increases in ventricular tissue Ca precede and accompany morphologic evidence of chronic myocardial degeneration and may be instrumental in the development of the ADR-induced cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4432914      PMCID: PMC1910923     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  An improved procedure for serum creatine phosphokinase determination.

Authors:  S B Rosalki
Journal:  J Lab Clin Med       Date:  1967-04

2.  [Toxicologic study and experimental antitumor activity of rubidomycin (13,057 R.P.)].

Authors:  R Maral; G Bourat; R Ducrot; J Fournel; P Ganter; L Julou; F Koenig; J Myon; S Pascal; J Pasquet; P Populaire; Y de Ratuld; G H Werner
Journal:  Pathol Biol       Date:  1967-10

3.  Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia.

Authors:  C Tan; H Tasaka; K P Yu; M L Murphy; D A Karnofsky
Journal:  Cancer       Date:  1967-03       Impact factor: 6.860

Review 4.  The intrinsic control of myocardial contraction--ionic factors.

Authors:  G A Langer
Journal:  N Engl J Med       Date:  1971-11-04       Impact factor: 91.245

5.  Cardiac toxicity of daunorubicin.

Authors:  G Bonadonna; S Monfardini
Journal:  Lancet       Date:  1969-04-19       Impact factor: 79.321

6.  Daunorubicin therapy in adult acute lymphatic leukemia.

Authors:  C D Bloomfield; R D Brunning; B J Kennedy
Journal:  Cancer       Date:  1972-07       Impact factor: 6.860

7.  Tissue electrolyte alteration in disseminated myocardial necrosis.

Authors:  D Lehr
Journal:  Ann N Y Acad Sci       Date:  1969-01-31       Impact factor: 5.691

8.  Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.

Authors:  A Di Marco; M Gaetani; B Scarpinato
Journal:  Cancer Chemother Rep       Date:  1969-02

9.  Dystrophic calcification of myocardium as conditioning factor in genesis of congestive heart failure. An experimental study.

Authors:  E Bajusz
Journal:  Am Heart J       Date:  1969-08       Impact factor: 4.749

10.  Myocardial calcium and magnesium in acute ischemic injury.

Authors:  A C Shen; R B Jennings
Journal:  Am J Pathol       Date:  1972-06       Impact factor: 4.307

View more
  33 in total

Review 1.  Doxorubicin effects on contractile structures and molecules.

Authors:  R Colombo; A Milzani; A Necco; G Vailati
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.058

2.  A digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes.

Authors:  E Chacon; R Ulrich; D Acosta
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

3.  Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system.

Authors:  S Hirano; N Agata; Y Hara; H Iguchi; M Shirai; H Tone; N Urakawa
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Lipid lowering: an important factor in preventing adriamycin-induced heart failure.

Authors:  N Iliskovic; P K Singal
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

5.  Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model.

Authors:  James C Lightfoot; Ralph B D'Agostino; Craig A Hamilton; Jennifer Jordan; Frank M Torti; Nancy D Kock; James Jordan; Susan Workman; W Gregory Hundley
Journal:  Circ Cardiovasc Imaging       Date:  2010-07-09       Impact factor: 7.792

6.  Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment.

Authors:  R Lenzhofer; U Ganzinger; H Rameis; K Moser
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

7.  The regulation of protein synthesis in heart muscle under normal conditions and in the adriamycin-cardiomyopathy.

Authors:  J Zähringer
Journal:  Klin Wochenschr       Date:  1981-12-01

8.  Covalent protein binding of reactive adriamycin metabolites in rat liver and rat heart microsomes.

Authors:  M E Scheulen; H Kappus; A Nienhaus; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

9.  Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI.

Authors:  D Piwnica-Worms; M L Chiu; J F Kronauge
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Adriamycin-induced leakage of lysosomal enzymes in vitro.

Authors:  P K Singal; B MacLeod; C M Deally
Journal:  Mol Cell Biochem       Date:  1988-05       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.